1
|
Grondek JF, Huffman K, Lee EJ, Cavichini M, Warter A, P Kalaw FG, Heinke A, Fan R, Cheng L, Sailor MJ, Freeman WR. Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA. Nanomedicine (Lond) 2022; 17:2089-2108. [PMID: 36748946 PMCID: PMC10031552 DOI: 10.2217/nnm-2022-0255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Accepted: 01/13/2023] [Indexed: 02/08/2023] Open
Abstract
Aim: To evaluate an intravitreally injected nanoparticle platform designed to deliver VEGF-A siRNA to inhibit retinal neovascular leakage as a new treatment for proliferative diabetic retinopathy and diabetic macular edema. Materials & methods: Fusogenic lipid-coated porous silicon nanoparticles loaded with VEGF-A siRNA, and pendant neovascular integrin-homing iRGD, were evaluated for efficacy by intravitreal injection in a rabbit model of retinal neovascularization. Results: For 12 weeks post-treatment, a reduction in vascular leakage was observed for treated diseased eyes versus control eyes (p = 0.0137), with a corresponding reduction in vitreous VEGF-A. Conclusion: Fusogenic lipid-coated porous silicon nanoparticles siRNA delivery provides persistent knockdown of VEGF-A and reduced leakage in a rabbit model of retinal neovascularization as a potential new intraocular therapeutic.
Collapse
Affiliation(s)
- Joel F Grondek
- Department of Chemistry & Biochemistry, University of California, San Diego, CA 92093, USA
| | - Kristyn Huffman
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Ella Jiyoon Lee
- Department of Chemistry & Biochemistry, University of California, San Diego, CA 92093, USA
| | - Melina Cavichini
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Alexandra Warter
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Fritz Gerald P Kalaw
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Anna Heinke
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Ruhan Fan
- Materials Science & Engineering, University of California, San Diego, CA 92093, USA
| | - Lingyun Cheng
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| | - Michael J Sailor
- Department of Chemistry & Biochemistry, University of California, San Diego, CA 92093, USA
- Materials Science & Engineering, University of California, San Diego, CA 92093, USA
| | - William R Freeman
- Department of Ophthalmology, Jacobs Retinal Center at Shiley Eye Institute, University of California, San Diego, CA 92093, USA
| |
Collapse
|
2
|
Jeong M, Jung Y, Yoon J, Kang J, Lee SH, Back W, Kim H, Sailor MJ, Kim D, Park JH. Porous Silicon-Based Nanomedicine for Simultaneous Management of Joint Inflammation and Bone Erosion in Rheumatoid Arthritis. ACS Nano 2022; 16:16118-16132. [PMID: 36214219 DOI: 10.1021/acsnano.2c04491] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
The lack of drugs that target both disease progression and tissue preservation makes it difficult to effectively manage rheumatoid arthritis (RA). Here, we report a porous silicon-based nanomedicine that efficiently delivers an antirheumatic drug to inflamed synovium while degrading into bone-remodeling products. Methotrexate (MTX) is loaded into the porous silicon nanoparticles using a calcium silicate based condenser chemistry. The calcium silicate-porous silicon nanoparticle constructs (pCaSiNPs) degrade and release the drug preferentially in an inflammatory environment. The biodegradation products of the pCaSiNP drug carrier are orthosilicic acid and calcium ions, which exhibit immunomodulatory and antiresorptive effects. In a mouse model of collagen-induced arthritis, systemically administered MTX-loaded pCaSiNPs accumulate in the inflamed joints and ameliorate the progression of RA at both early and established stages of the disease. The disease state readouts show that the combination is more effective than the monotherapies.
Collapse
Affiliation(s)
- Moonkyoung Jeong
- Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon34141, Republic of Korea
| | - Yuna Jung
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul02447, Republic of Korea
| | - Junyong Yoon
- Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon34141, Republic of Korea
| | | | - Seo Hyeon Lee
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul02447, Republic of Korea
| | - Woojin Back
- Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon34141, Republic of Korea
| | - Hyoyeon Kim
- Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon34141, Republic of Korea
| | | | - Dokyoung Kim
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul02447, Republic of Korea
| | - Ji-Ho Park
- Department of Bio and Brain Engineering and KAIST Institute for Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST), Daejeon34141, Republic of Korea
| |
Collapse
|
3
|
Kang RH, Park J, Kim J, Chowdhury T, Oh JH, Kim J, Shin J, Kim M, Park CK, Lee S, Lee JY, Kim D. A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma. ACS Biomater Sci Eng 2021; 8:4163-4174. [PMID: 34196517 DOI: 10.1021/acsbiomaterials.1c00653] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Glioblastoma multiforme (GBM) is the most aggressive malignant tumor. It is difficult to regulate GBM using conventional chemotherapy-based methods due to its anatomical structure specificity, low drug targeting ability, and limited penetration depth capability to reach the tumor interior. Numerous approaches have been proposed to overcome such issues, including nanoparticle-based drug delivery system (DDS) with the development of GBM site targeting and penetration depth enhancing moieties (e.g., peptides, sugars, proteins, etc.). In this study, we prepared four different types of nanoparticles, which are based on porous silicon nanoparticles (pSiNPs) incorporating polyethylene glycol (PEG), iRGD peptide (well-known cancer targeting peptide), and SIWV tetra-peptide (a recently disclosed GBM-targeting peptide), and analyzed their deep-tumor penetration abilities in cell spheroids, in GBM patient-derived tumoroids, and in GBM xenograft mice. We found that SIWV tetra-peptide significantly enhanced the penetration depth of pSiNPs, and its therapeutic formulation (temozolomide-loaded/SIWV-functionalized pSiNPs) showed a higher anticancer efficacy compared with other formulations. These findings hold great promise for the development of nanotherapeutics and peptide-conjugated drugs for GBM.
Collapse
Affiliation(s)
- Rae Hyung Kang
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Jinju Park
- Neural Development and Anomaly Laboratory, Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Jieun Kim
- Neural Development and Anomaly Laboratory, Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Tamrin Chowdhury
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Ji Hyeon Oh
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Jaehoon Kim
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Jaeha Shin
- R&D Center, Pensees Inc., Seoul 04043, Republic of Korea
| | - Minji Kim
- R&D Center, Pensees Inc., Seoul 04043, Republic of Korea
| | - Chul-Kee Park
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Sungjun Lee
- R&D Center, Pensees Inc., Seoul 04043, Republic of Korea
| | - Ji Yeoun Lee
- Neural Development and Anomaly Laboratory, Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.,Division of Pediatric Neurosurgery, Seoul National University Children's Hospital, Seoul 03080, Republic of Korea
| | - Dokyoung Kim
- Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.,Department of Anatomy and Neurobiology, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.,Center for Converging Humanities, Kyung Hee University, Seoul 02447, Republic of Korea.,Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Kyung Hee University, Seoul 02447, Republic of Korea.,KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul 02447, Republic of Korea
| |
Collapse
|
4
|
Xie Y, Zeng X, Wu X, Hu J, Zhu Y, Yang X. Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest. Nanomedicine (Lond) 2018; 13:887-898. [PMID: 29473458 DOI: 10.2217/nnm-2017-0395] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIM To study the effects of combinational treatment of hyperbaric oxygen (HBO) and nanotemozolomide in glioma. MATERIALS & METHODS Temozolomide (TMZ)-loaded porous silicon nanoparticles (TMZ/PSi NPs) were prepared. In vitro and in vivo evaluations were performed. RESULTS The cell uptake of TMZ/PSi NPs could be tracked by autofluorescence of porous silicon. The concentration of oxygen in tumor was improved and the antitumor rate was increased to 84.2% in the TMZ/PSi NPs combined with HBO group. The viability of hypoxia-induced glioma C6 cells was decreased and cell cycle was arrested at G2/M phase in response to TMZ/PSi NPs treatment with HBO compared with continuous treatment with hypoxia. CONCLUSION The combinational treatment of TMZ/PSi NPs and HBO could be a promising therapeutic strategy for glioma.
Collapse
Affiliation(s)
- Yuanyuan Xie
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| | - Xiaofan Zeng
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| | - Xian Wu
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| | - Jun Hu
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| | - Yanhong Zhu
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| | - Xiangliang Yang
- College of Life Science & Technology, National Engineering Research Center for Nanomedicine, Huazhong University of Science & Technology, Wuhan, 430074, PR China
| |
Collapse
|
5
|
Liu W, Chaix A, Gary-Bobo M, Angeletti B, Masion A, Da Silva A, Daurat M, Lichon L, Garcia M, Morère A, El Cheikh K, Durand JO, Cunin F, Auffan M. Stealth Biocompatible Si-Based Nanoparticles for Biomedical Applications. Nanomaterials (Basel) 2017; 7:E288. [PMID: 28946628 PMCID: PMC5666453 DOI: 10.3390/nano7100288] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 09/18/2017] [Accepted: 09/20/2017] [Indexed: 01/05/2023]
Abstract
A challenge regarding the design of nanocarriers for drug delivery is to prevent their recognition by the immune system. To improve the blood residence time and prevent their capture by organs, nanoparticles can be designed with stealth properties using polymeric coating. In this study, we focused on the influence of surface modification with polyethylene glycol and/or mannose on the stealth behavior of porous silicon nanoparticles (pSiNP, ~200 nm). In vivo biodistribution of pSiNPs formulations were evaluated in mice 5 h after intravenous injection. Results indicated that the distribution in the organs was surface functionalization-dependent. Pristine pSiNPs and PEGylated pSiNPs were distributed mainly in the liver and spleen, while mannose-functionalized pSiNPs escaped capture by the spleen, and had higher blood retention. The most efficient stealth behavior was observed with PEGylated pSiNPs anchored with mannose that were the most excreted in urine at 5 h. The biodegradation kinetics evaluated in vitro were in agreement with these in vivo observations. The biocompatibility of the pristine and functionalized pSiNPs was confirmed in vitro on human cell lines and in vivo by cytotoxic and systemic inflammation investigations, respectively. With their biocompatibility, biodegradability, and stealth properties, the pSiNPs functionalized with mannose and PEG show promising potential for biomedical applications.
Collapse
Affiliation(s)
- Wei Liu
- CNRS, IRD, Coll de France, CEREGE, Aix Marseille Université, 13545, Aix en Provence, France.
| | - Arnaud Chaix
- Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-ENSCM-UM, Ecole Nationale Supérieure de Chimie Montpellier, 8 rue de l'Ecole Normale, 34296 Montpellier, France.
| | - Magali Gary-Bobo
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Bernard Angeletti
- CNRS, IRD, Coll de France, CEREGE, Aix Marseille Université, 13545, Aix en Provence, France.
| | - Armand Masion
- CNRS, IRD, Coll de France, CEREGE, Aix Marseille Université, 13545, Aix en Provence, France.
| | - Afitz Da Silva
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
- NanoMedSyn, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Morgane Daurat
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
- NanoMedSyn, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Laure Lichon
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Marcel Garcia
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Alain Morère
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-UM, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Khaled El Cheikh
- NanoMedSyn, 15 Avenue Charles Flahault, BP 14491, 34093 Montpellier CEDEX 05, France.
| | - Jean-Olivier Durand
- Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-ENSCM-UM, Ecole Nationale Supérieure de Chimie Montpellier, 8 rue de l'Ecole Normale, 34296 Montpellier, France.
| | - Frédérique Cunin
- Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-ENSCM-UM, Ecole Nationale Supérieure de Chimie Montpellier, 8 rue de l'Ecole Normale, 34296 Montpellier, France.
| | - Mélanie Auffan
- CNRS, IRD, Coll de France, CEREGE, Aix Marseille Université, 13545, Aix en Provence, France.
| |
Collapse
|